Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
- Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
- Drug Approvals
- Clinical Trial Calendar

Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard

Crypto
Cryptocurrency
Blockchain

Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies

Politics
US
World
White House
Elections
General News

Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard

Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health

Slide Shows

Entertainment
Top Stories
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre

Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services

Premium
Intelligent Investor
Biotech Investor NEW
Login

Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us

Business
Corp. News
- Latest Headlines
- Biotech
- Investors
- Stock Alerts
- IPOs
- M&A
Industry News
- Technology
- Software
- Banking
- Automotive
- Energy
- More
Corp. Calendars
Earnings Calendar
FDA Calendars
- Drug Approvals
- Clinical Trial Calendar
Ratings Changes
Economy
- US
- Europe
- Asia
- Global
- Economic Calendar
- Economic Scorecard
Crypto
- Cryptocurrency
- Blockchain
Markets
Market News
Politics
- US
- World
- White House
- Elections
- General News
Forex
Health
Health News
Slide Shows
Entertainment
Entertainment News
- Top Stories
Music News
- Pop
- Rock
- Classic Rock
- Rap/Hip-Hop
- Country
- Alternative
- Oldies
- All Genre
Content Licensing
Premium
More

Pfizer Inc. (PFE)

Pfizer: Phase 3 Trial Shows TALZENNA + XTANDI Cut Progression Risk 52% In HRR-mutated MCSPC 5/30/2026 8:52:21 AM

Pfizer’s TALAPRO-3 Trial Shows TALZENNA + XTANDI Cuts Risk Of Progression Or Death By 52% In HRR-Mutated MCSPC 5/30/2026 8:32:28 AM

Weekly Buzz: AZN, JNJ Get FDA Nod; LLY To Acquire Curevo; APGE Advances Zumilokibart 5/29/2026 10:39:40 AM

Pfizer Reports Positive Seven-Year Follow-up Data For LORBRENA In Lung Cancer Trial 5/29/2026 8:31:50 AM

Pfizer Reports Landmark Seven-Year CROWN Trial Results For LORBRENA In ALK-Positive NSCLC 5/29/2026 8:10:33 AM

Pfizer Enters Deal With Innovent Biologics To Co-Develop Oncology Medicines 5/29/2026 3:57:45 AM

Pfizer Enters Strategic Deal With Innovent Biologics To Co-Develop Oncology Medicines 5/29/2026 3:47:40 AM

Pfizer And Innovent Sign Global Deal On Early-Stage Cancer Therapies 5/28/2026 10:30:31 PM

Merck Reports Positive CHMP Recommendation For KEYTRUDA Plus Padcev 5/22/2026 8:27:11 AM

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Phase 2 Data 5/20/2026 7:17:12 AM

Pfizer: EC Approves HYMPAVZI For Treatment Of Hemophilia A Or B With Inhibitors 5/13/2026 6:52:02 AM

Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu 5/12/2026 7:50:12 AM

Arvinas, Pfizer Enter License Deal With Rigel Pharma To Develop VEPPANU 5/12/2026 7:09:36 AM

Pfizer Q1 Profit Drops, Revenues Rise; Backs FY26 Outlook - Update 5/5/2026 7:30:02 AM

Pfizer Inc. Profit Retreats In Q1 5/5/2026 6:53:12 AM

Pfizer Q1 Reported EPS $0.47; Adj EPS $0.75 5/5/2026 6:48:17 AM

Pfizer Q1 26 Earnings Conference Call At 10:00 AM ET 5/5/2026 6:00:18 AM

Pfizer Reports Positive Results From Phase 3 MagnetisMM-5 Study Of ELREXFIO In Multiple Myeloma 4/29/2026 7:11:32 AM

Pfizer’s ELREXFIO Shows Significant PFS Benefit In Phase 3 MagnetisMM-5 Trial For Multiple Myeloma 4/29/2026 6:47:14 AM

Pfizer Settles Patent Disputes, Extends VYNDAMAX Exclusivity To 2031 4/28/2026 12:06:43 PM

- 1
- 2
- Next »

Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us | Contact Us | Privacy | Sitemap